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Cardiac safety results from a phase II, open-label,
multicenter, pilot study of two docetaxel-based
regimens plus bevacizumab for the adjuvant
treatment of subjects with node-positive or
high-risk node-negative breast cancer
Sara A Hurvitz1*, Linda D Bosserman2, David Chan3, Christopher T Hagenstad4, Frederick C Kass5,
Frederick P Smith6, Gladys I Rodriguez7, Barrett H Childs8 and Dennis J Slamon1
Abstract
Purpose: Adding antiangiogenic therapy to standard chemotherapy has improved response rates and
progression-free survival in metastatic breast cancer (BC) patients. This phase II study evaluated cardiac safety of
bevacizumab with/without trastuzumab with two docetaxel-based regimens in early BC.
Methods: 127 women with non-metastatic node-positive or high-risk node-negative BC were enrolled. Women
with human epidermal growth factor receptor 2 (HER2)-negative BC (n = 93) received docetaxel/doxorubicin/
cyclophosphamide (TAC) + bevacizumab, while women with HER2-positive disease (n = 34) received docetaxel/
carboplatin/trastuzumab (TCH) + bevacizumab, every 3 weeks for six cycles. Maintenance therapy with bevacizumab
alone or bevacizumab plus trastuzumab, respectively, was given every 3 weeks for 52 weeks. The primary objective
was to evaluate cardiac safety, as measured by the incidence of≥ grade 3 clinical congestive heart failure (CHF); the
secondary objective was assessment of safety and toxicity.
Results: At least one cardiac adverse event (AE; CHF, cardiomyopathy, or left ventricular dysfunction) was reported in
26.1% of TAC (n = 92) and 17.6% of TCH subjects (n = 34); there were no cardiac deaths. ≥ Grade 3 clinical CHF was
observed in 4.3% in the TAC plus bevacizumab stratum and 0% in the TCH plus bevacizumab stratum. A≥ grade 3
treatment-emergent AE (any kind) related to study treatment was observed in 59.8% in the TAC with bevacizumab and
52.9% in the TCH plus bevacizumab stratum.
Conclusion: Adding bevacizumab to a docetaxel-based regimen with trastuzumab did not appear to increase
cardiotoxicity.
Trial registration: ClinicalTrials.gov Identifier: NCT00446030, registered March 8, 2007.
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Introduction
Breast cancer mortality has declined over the past 2
decades; however, it still remains the most common type
of cancer in women, accounting for an estimated 29% of
all new cases (Siegel et al. 2014). The 5-year survival rate
for women with breast cancer is 99% for those with
localized disease and 84% for regional disease, and only
24% in patients with distant disease (Siegel et al. 2014).
Several studies in human epidermal growth factor re-
ceptor 2 (HER2)-normal metastatic breast cancer have
reported that the addition of bevacizumab to chemo-
therapy improves response rates and progression-free
survival compared with chemotherapy alone (Miller
et al. 2007; Robert et al. 2009; Brufsky et al. 2011; Pivot
et al. 2011). Preclinical evidence also suggests that the
combination of monoclonal antibodies that target HER2
and vascular endothelial growth factor (VEGF) may act
synergistically in HER2 overexpressing cancers (Sweeney
et al. 2001; Pegram et al. 2004).
The present study was primarily initiated to evaluate
the cardiac safety of bevacizumab when given in combin-
ation with a standard-of-care anthracycline-based treat-
ment—docetaxel, doxorubicin, cyclophosphamide (TAC)
(Mackey et al. 2013)—in the adjuvant setting. At the time
of study initiation, larger studies, such as Eastern
Cooperative Oncology Group (ECOG) E5103 (National
Cancer Institute), were being planned to evaluate bevaci-
zumab in adjuvant, HER2-negative breast cancer patients.
Combining anti-VEGF therapy with anthracycline-based
chemotherapy raises concerns regarding cardiac safety,
given the association of doxorubicin with an increased risk
of congestive heart failure (CHF), and the tendency of
bevacizumab to increase blood pressure and, as a result,
cardiac “afterload”. The theoretical concern is that
a bevacizumab-associated increase in afterload could
unmask clinically occult cardiac toxicity from anthracy-
cline, and effectively increase the rate of clinical cardiac
adverse events (AEs). The present study was designed in
part to provide initial safety data regarding the combin-
ation of an anthracycline with bevacizumab for the
larger planned studies.
For HER2-positive breast cancer, the use of adjuvant
trastuzumab has been shown to improve disease-free
survival (DFS) and overall survival (OS) when added to
standard chemotherapy (Romond et al. 2005; Slamon
et al. 2011). Preclinical data suggesting that HER2-
positive breast cancer is particularly reliant on neoangio-
genesis (Davidson et al. 1987; Epstein et al. 2002; Yen
et al. 2000; Konecny et al. 2004) led to the initiation of
several clinical trials that evaluated the combination of
trastuzumab and bevacizumab. One of the first of these
was a phase II study that enrolled 50 subjects with
HER2-positive metastatic breast cancer which reported
an asymptomatic cardiac event rate of 36% with a grade
4 cardiac event in 2.0% of subjects (Hurvitz et al. 2009). At
the time of the present study’s initiation, planning was
underway for BETH (BEvacizumab and Trastuzumab
Adjuvant Therapy in HER2-positive Breast Cancer)
(Slamon et al. 2013), a large phase III adjuvant study in
which patients with HER2-positive breast cancer were
randomly assigned to receive docetaxel, carboplatin,
and trastuzumab (TCH) with or without bevacizumab.
Given that (1) trastuzumab is associated with a low
(0.4%) risk of heart failure when given in combination
with docetaxel and carboplatin (Slamon et al. 2011),
and (2) it is not known if adding bevacizumab to trastu-
zumab increases the risk of heart failure, our study
included a HER2-positive cohort to gauge the cardiac
safety of TCH plus bevacizumab.
Patients and methods
This was a phase II, parallel-group, open-label, non-
comparative, multicenter, pilot study (clinicaltrials.gov:
NCT00365365). The primary objective was to evaluate the
cardiac safety of bevacizumab with/without trastuzumab,
as measured by the incidence of ≥ grade 3 clinical CHF,
when administered with two different docetaxel-based
combination regimens for the adjuvant treatment of
subjects with node-positive or high-risk node-negative
breast cancer. The secondary objectives were to evalu-
ate the safety and toxicity of these same treatments. The
study was originally designed to also evaluate DFS and
OS; however, the study was terminated early and follow-
up was shortened from 10 years to 2 years; therefore, DFS
and OS were not evaluated (second amendment to the
protocol). This study was conducted in accordance with
Good Clinical Practice and in compliance with the
Helsinki Declaration and all applicable local regulatory
requirements. Before the performance of any study-related
procedures or assessments, each subject signed an institu-
tional review board (IRB)–approved informed consent
form (ICF). IRB approval was granted by UCLA-IRB for
subjects enrolled at UCLA and by Western IRB for sub-
jects enrolled at other participating sites.
Subjects were assigned at the time of enrollment to
one of two strata: stratum 1 consisted of women with
HER2-negative breast cancer who received TAC with
bevacizumab while stratum 2 consisted of women with
HER2-positive breast cancer who received TCH with
bevacizumab (Figure 1). Key inclusion and exclusion
criteria are shown in Table 1.
Safety parameters assessed included AEs (nonserious
and serious treatment-emergent AEs [TEAEs]) with par-
ticular emphasis on cardiac disorders (including grade 3/
4 clinical CHF), hematologic disorders, and deaths. A
study goal was to categorize CHF by objective criteria
rather than using New York Heart Association (NYHA)
functional classification, which primarily utilizes
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physician judgment. Left ventricular ejection fraction
(LVEF) was assessed by multigated acquisition scan
(MUGA) or echocardiogram (echo). Assessments were
performed within 35 days of study enrollment between
cycles 3 and 4, as well as 6 and 7; every third cycle dur-
ing maintenance therapy for trastuzumab/bevacizumab
in stratum 2 only; at end of therapy; at post-therapy
follow-up/withdrawal; and every 6 months for the 2-year
follow-up period. Subjects with LVEF below the institu-
tion’s lower limit of normal and a > 10% change from the
previous measurement were discontinued from the study.
CHF was classified using the National Cancer Institute
(NCI) Common Terminology Criteria for Adverse Events
(CTCAE) version 3.0. Signs and symptoms of CHF were
monitored during the course of trastuzumab therapy as
well. Other safety assessments included physical examin-
ation, vital signs, and clinical laboratory tests.
It was anticipated that the rate of CHF for bevacizu-
mab would not exceed 2%, while a level of toxicity above
10% would be of great concern. To allow for 5% noneva-
luable subjects, the accrual target was 75 subjects per
treatment stratum. This was based on a Simon’s 2-stage
MiniMax design for a hypothesis test of the null hypothesis
of a toxicity-free rate of 90% versus an alternative of 98%
with 1-sided significance level of 5% and power of 90%.
Results
All subjects were women; the majority were Caucasian
and under the age of 65 years, with good performance
status. Detailed demographic and baseline characteristics
for the safety population are presented in Table 2.
Among the planned 150 subjects, a total of 127 were
enrolled between March and November 2007. At that
time, recruitment to the HER2-negative stratum was
complete, but enrollment into the HER2-positive stratum
was placed on hold while awaiting an amendment that
would randomize these subjects into one of two arms—
TCH plus bevacizumab (stratum 2 of the current proto-
col) or an anthracycline-containing arm that was to be
used in BETH in some parts of the world. By November
2008, it was determined that this amendment would not
be necessary, as there were sufficient safety data already
available from the TCH plus bevacizumab stratum of this
study, to analyze for purposes of moving forward with the
BETH trial and thus the trial was terminated. Overall, a
total of 93 subjects in the TAC plus bevacizumab stratum
and 34 in the TCH plus bevacizumab stratum were en-
rolled. One subject in the TAC stratum requested to be dis-
continued following enrollment but prior to receiving any
treatment. Consequently, the safety population consisted of
126 subjects. Among the 93 enrolled subjects in the TAC
plus bevacizumab stratum, 52.7% completed study treat-
ment and 67.7% completed follow-up. Among the 46.2%
who discontinued treatment, the majority discontinued
after cycle 6. The reasons for discontinuation of treatment
were AEs (31.2%), subject request (9.7%), poor compliance
(1.1%), and “other” (4.3%). Among the 34 enrolled subjects
in the TCH plus bevacizumab stratum, 73.5% completed
Figure 1 Study design. Abbreviations: HER2/neu = human epidermal growth factor receptor-2; TAC = docetaxel, doxorubicin, cyclophosphamide;
TCH = docetaxel, carboplatin, trastuzumab.
Table 1 Major inclusion and exclusion criteria
Major inclusion criteria Major exclusion criteria
● Female 18–70 years old ● History of systemic anticancer therapy for invasive breast cancer,
chemotherapy, or radiation therapy
● HER2/neu positive or negative, histologically proven, lymph
node-positive or high-risk lymph node-negative breast cancer
● Cardiac disease or poorly controlled hypertension
● Definitive breast surgery within 28 to 60 days consisting of mastectomy;
breast conserving surgery with axillary lymph node dissection or sentinel
lymph node biopsy for operable breast cancer (T1-3, N0-1, M0)
● Other serious medical issues
● Normal cardiac, hematologic, and liver function ● Minor surgical procedure within 7 days or major surgical procedure
within 28 days prior to day 1 of study treatment or any anticipated
surgical procedure during the chemotherapy portion of the study
Hurvitz et al. SpringerPlus 2014, 3:244 Page 3 of 9
http://www.springerplus.com/content/3/1/244
study treatment and 73.5% completed follow-up. A majority
of the 26.5% who discontinued from treatment did so after
cycle 6. The reasons for discontinuation of treatment were
AEs (23.5%) and subject request (2.9%).
Cardiac toxicity
In the TAC plus bevacizumab stratum (n = 92), at least
one cardiac disorder of any grade was reported as an AE
in 26.1% of subjects (95% confidence interval [CI], 17.5–
36.3) and in the TCH plus bevacizumab stratum (n = 34)
in 17.6% of subjects (95% CI, 6.8–34.5). There were no
cardiac deaths in either stratum (Table 3). In the TAC
plus bevacizumab stratum, 4.3%, and in the TCH plus
bevacizumab stratum, 0%, had clinical CHF ≥ grade 3.
One subject in the TAC plus bevacizumab stratum ex-
perienced two cardiac events, which were clinical CHF
and cardiomyopathy. An LVEF reduction of > 10% or an
LVEF below the lower limit of normal was seen postba-
seline for 23.9% of subjects (95% CI, 15.6–33.9) in the
Table 2 Demographic and baseline characteristics: safety
population
Treatment TAC +
Bevacizumab
(n = 92)
TCH +
Bevacizumab
(n = 34)
Total
(N = 126)
Gender, female,
n (%)
92 (100.0) 34 (100.0) 126 (100.0)
Age, years
n 92 34 126
Mean 50.7 49.9 50.5
SD 10.09 9.38 9.88
Median 51.5 51.5 51.5
Min, max 28, 70 26, 65 26, 70
Age group,
years, n (%)
< 65 84 (91.3) 33 (97.1) 117 (92.9)
≥ 65 8 (8.7) 1 (2.9) 9 (7.1)
Race, n (%)
Caucasian 82 (89.1) 23 (67.6) 105 (83.3)
Black 2 (2.2) 3 (8.8) 5 (4.0)
Asian 2 (2.2) 6 (17.8) 8 (6.3)
Other 6 (6.5) 2 (5.9) 8 (6.3)
Height, cm
n 91 34 125
Mean 164.7 162.3 164.0
SD 7.30 6.99 7.27
Median 165.0 161.0 165.0
Min, max 147, 182 152, 180 147, 182
Weight, kg
n 92 34 126
Mean 76.37 72.09 75.21
SD 17.590 14.766 16.925
Median 72.65 70.20 71.85
Min, max 46.1, 136.8 43.6, 109.5 43.6, 136.8
Body surface area, m2
n 91 34 125
Mean 1.826 1.764 1.809
SD 0.2021 0.1716 0.1956
Median 1.810 1.770 1.790
Min, max 1.47, 2.44 1.38, 2.11 1.38, 2.44
ECOG PS, n (%)
0 86 (93.5) 30 (88.2) 116 (92.1)
1 6 (6.5) 4 (11.8) 10 (7.9)
Surgical
procedure, n (%)
Lumpectomy 48 (52.2) 25 (73.5) 73 (57.9)
Mastectomy 46 (50.0) 11 (32.4) 57 (45.2)
Other 37 (40.2) 14 (41.2) 51 (40.5)
Table 2 Demographic and baseline characteristics: safety
population (Continued)
Infiltrating ductal
carcinoma, n (%)
76 (82.6) 32 (94.1) 108 (85.7)
Nuclear grade,
n (%)
G3 49 (53.3) 20 (58.8) 69 (54.8)
G2 31 (33.7) 14 (41.2) 45 (35.7)
Disease stage at
diagnosis, n (%)
IIA 42 (45.7) 12 (35.3) 54 (42.9)
IIB 22 (23.9) 11 (32.4) 33 (26.2)
TNM staging,
n (%)
T1N0M0 0 12 (35.3) 12 (9.5)
T1N1M0 20 (21.7) 0 20 (15.9)
T2N0M0 23 (25.0) 8 (23.5) 31 (24.6)
T2N1M0 22 (23.9) 7 (20.6) 29 (23.0)
Hormone receptor
status, n (%)
ER+/PR+ 47 (51.1) 13 (38.2) 60 (47.6)
ER+/PR- 14 (15.2) 12 (38.2) 26 (20.6)
ER-/PR- 18 (31.5) 7 (20.6) 25 (19.8)
ER-/PR+ 2 (2.2) 1 (2.9) 3 (2.4)
HER2/neu
receptor, n (%)
Negative 91 (98.9) 0 91 (72.2)
Positive 1 (1.1) 34 (100) 35 (27.8)
Abbreviations: ECOG PS = Eastern Cooperative Oncology Group performance
status; ER = estrogen receptor; HER2 = human epidermal growth factor
receptor; PR = progesterone receptor; SD = standard deviation; TAC = docetaxel,
doxorubicin, cyclophosphamide; TCH = docetaxel, carboplatin, trastuzumab;
TNM= tumor, node, metastasis.
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TAC plus bevacizumab stratum and for 23.5% of sub-
jects (95% CI, 10.7–41.2) in the TCH plus bevacizumab
stratum (Table 3).
Treatment-emergent adverse events (TEAE)
All subjects experienced at least one TEAE and at least
one TEAE was considered related to study treatment
(Table 4). At least one ≥ grade 3 TEAE was reported for
67.4% of subjects in the TAC stratum and 61.8% in
the TCH stratum (Table 5). A TEAE leading to death
occurred in three subjects: two in the TAC stratum (clos-
tridial infection and septic shock) and one in the TCH
stratum (ischemic cerebral infarction). The clostridial in-
fection was considered related to docetaxel, bevacizumab,
and other study treatment; septic shock was considered
related to docetaxel and other treatment; and ischemic
cerebral infarction was considered related to docetaxel
and bevacizumab. Other bevacizumab-related ≥ grade 3
AEs of Importance in the postsurgical setting include
postoperative wound infection in two subjects (2.2%),
and wound, impaired healing, and wound dehiscence
each in one subject (1.1%). Clostridial infection, neutro-
penic infection, and perirectal abscess each occurred in
one subject (1.1%).
Discussion
In the present study, cardiac safety was manageable in
both treatment strata, with the number of ≥ grade 3
events below the prespecified threshold of discontinu-
ation for these combinations. Twenty-four subjects
(26.1%) treated with TAC plus bevacizumab and six
subjects (17.6%) treated with TCH plus bevacizumab
experienced a cardiac AE. ≥ Grade 3 clinical CHF was
experienced by four subjects (4.3%) treated with TAC
plus bevacizumab but no subjects (0%) treated with
TCH plus bevacizumab. The incidence of CHF in the
TAC stratum in the present study was higher than
observed in similar AC-T stratum of the Breast Cancer
International Research Group (BCIRG) 006 study (Slamon
et al. 2011). Despite using more stringent criteria and
review by a blinded, independent cardiac review panel,
the rates of CHF in the non-trastuzumab and the non-
anthracycline containing strata of BCIRG 006 were 0.7%
of those treated with doxorubicin and cyclophospha-
mide followed by docetaxel and 0.4% with TCH, re-
spectively (Slamon et al. 2011).
In addition, more subjects treated with TCH plus bev-
acizumab in our study experienced LVEF reduction >
10% compared with subjects enrolled in the TCH-alone
arm of BCIRG 006 (23.5% vs. 9.4%, respectively) and
more subjects treated with TAC plus bevacizumab in
our study experienced LVEF reduction > 10% compared
with the AC-T arm of BCIRG 006 (23.9% vs. 11.2%,
respectively) (Slamon et al. 2011). However, the higher
rate of decrease in LVEF > 10% in our study compared
with that in BCIRG 006 might be because BCIRG 006
does not include patients whose LVEF dropped to < 10%
but has measurements less than the lower limit of nor-
mal, while our study did. In the TAC plus bevacizumab
stratum of the current study, 4.3% of subjects experi-
enced CHF. This is higher than rates of 0%–2% observed
in other anthracycline-based adjuvant studies (Martin
et al. 2003; Henderson et al. 2003; Citron et al. 2003),
including rates of 3% in the BCIRG 001 study and 0.2% in
the Spanish Breast Cancer Research Group (GEICAM)
9805 study with TAC (Mackey et al. 2013; Martin and Hall
2005). Our rate is also higher than the 1.6% determined
from a meta-analysis of 3784 patients with breast cancer
treated with bevacizumab (Choueiri et al. 2011). This
difference may be a result of the concomitant treatment
Table 3 Incidence of cardiac adverse events: safety population
TAC + Bevacizumab (n = 92) TCH + Bevacizumab (n = 34) Total (N = 126)
na (%) 95% CIb na (%) 95% CIb na (%) 95% CIb
Subjects with cardiac disordersc 24 (26.1) (17.5–36.3) 6 (17.6) (6.8–34.5) 30 (23.8) (16.7–32.2)
Subjects with clinical CHF (≥grade 3)d 4 (4.3) (1.2–10.8) 0 (0.0–10.3) 4 (3.2) (0.9–7.9)
Cardiac failure congestive 3 (3.3) (0.7–9.2) 0 (0.0–10.3) 3 (2.4) (0.5–6.8)
Cardiomyopathy 1 (1.1) (0.0–5.9) 0 (0.0–10.3) 1 (0.8) (0.0–4.3)
Left ventricular dysfunction 1 (1.1) (0.0–5.9) 0 (0.0–10.3) 1 (0.8) (0.0–4.3)
Subjects with LVEF reduction > 10% or LVEF
< lower limit of normale
22 (23.9) (15.6–33.9) 8 (23.5) (10.7–41.2) 30 (23.8) (16.7–32.2)
Cardiac deathf 0 (0.0–3.9) 0 (0.0–10.3) 0 (0.0–2.9)
Abbreviations: CI = confidence interval; CHF = congestive heart failure; LVEF = left ventricular ejection fraction; TAC = docetaxel, doxorubicin, cyclophosphamide;
TCH = docetaxel, carboplatin, trastuzumab.
aNumber of subjects who had at least one event at any time during the study.
bExact 2-sided binomial CI.
cIncludes all subjects with at least one event in the system organ class of Cardiac Disorders.
dIncludes subjects with at least one ≥ grade 3 event with specified preferred terms.
eIncludes subjects with LVEF absolute reduction of > 10% from baseline at any time postbaseline, or LVEF < lower limit of normal at any time postbaseline.
fIncludes subjects with a cardiac disorder event with outcome of death.
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with an anthracycline in the majority of subjects in our
study (73%) compared with 16% of patients in the meta-
analysis that likely contributed to the higher rate of
CHF in our study (Choueiri et al. 2011). The phase III
study AVEREL (Avastin [Bevacizumab] in Combination
With Herceptin [Trastuzumab]/Docetaxel in Patients
With HER2-Positive Metastatic Breast Cancer) enrolled
424 patients with HER2-positive metastatic breast cancer
who were randomly assigned to docetaxel plus trastuzu-
mab with or without bevacizumab. ≥ Grade 3 CHF was
noted in 5.1% of patients in the bevacizumab arm com-
pared with 2.9% in the control arm (Gianni et al. 2013).
Table 4 Treatment-emergent adverse events (aes) (all grades) reported by ≥20% of subjects in a treatment stratum
Preferred term, n (%) TAC + Bevacizumab (n = 92) TCH + Bevacizumab (n = 34) Total (N = 126)
Subjects with at least one AE 92 (100.0) 34 (100.0) 126 (100.0)
Fatigue 79 (85.9) 30 (88.2) 109 (86.5)
Nausea 75 (81.5) 28 (82.4) 103 (81.7)
Alopecia 73 (79.3) 28 (82.4) 101 (80.2)
Diarrhea 57 (62.0) 24 (70.6) 81 (64.3)
Arthralgia 47 (51.1) 20 (58.8) 67 (53.2)
Constipation 46 (50.0) 18 (52.9) 64 (50.8)
Epistaxis 43 (46.7) 18 (52.9) 61 (48.4)
Headache 40 (43.5) 17 (50.0) 57 (45.2)
Insomnia 39 (42.4) 16 (47.1) 55 (43.7)
Vomiting 39 (42.4) 12 (35.3) 51 (40.5)
Decreased appetite 38 (41.3) 10 (29.4) 48 (38.1)
Hot flush 33 (35.9) 15 (44.1) 48 (38.1)
Anemia 33 (35.9) 13 (38.2) 46 (36.5)
Lacrimation increased 31 (33.7) 14 (41.2) 45 (35.7)
Neutropenia 39 (42.4) 5 (14.7) 44 (34.9)
Dysgeusia 25 (27.2) 17 (50.0) 42 (33.3)
Stomatitis 30 (32.6) 12 (35.3) 42 (33.3)
Cough 30 (32.6) 8 (23.5) 38 (30.2)
Thrombocytopenia 25 (27.2) 13 (38.2) 38 (30.2)
Dyspepsia 24 (26.1) 13 (38.2) 37 (29.4)
Hypertension 26 (28.3) 11 (32.4) 37 (29.4)
Bone pain 31 (33.7) 5 (14.7) 36 (28.6)
Dyspnea 23 (25.0) 7 (20.6) 30 (23.8)
Oropharyngeal pain 17 (18.5) 10 (29.4) 27 (21.4)
Depression 19 (20.7) 6 (17.6) 25 (19.8)
Leukopenia 19 (20.7) 5 (14.7) 24 (19.0)
Mucosal inflammation 16 (17.4) 7 (20.6) 23 (18.3)
Pain in extremity 20 (21.7) 3 (8.8) 23 (18.3)
Rash 14 (15.2) 9 (26.5) 23 (18.3)
Back pain 14 (15.2) 7 (20.6) 21 (16.7)
Musculoskeletal pain 13 (14.1) 8 (23.5) 21 (16.7)
Edema peripheral 11 (12.0) 7 (20.6) 18 (14.3)
Sinusitis 11 (12.0) 7 (20.6) 18 (14.3)
UTI 10 (10.9) 8 (23.5) 18 (14.3)
Nail disorder 9 (9.8) 8 (23.5) 17 (13.5)
Dry skin 8 (8.7) 8 (23.5) 16 (12.7)
Alanine aminotransferase increased 3 (3.3) 7 (20.6) 10 (7.9)
Abbreviations: TAC = docetaxel, doxorubicin, cyclophosphamide; TCH = docetaxel, carboplatin, trastuzumab; UTI = urinary tract infection.
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The small number of subjects in the current study and
different assessment methods make cross-trial comparisons
of cardiac effects difficult. However, the higher overall
rate of CHF, particularly LVEF reduction > 10% or LVEF
below the lower limit of normal observed in our study,
is a concern. It should be noted that this study was con-
ducted in 2007–2008, prior to the US Food and Drug
Administration’s November 2011 decision to revoke ap-
proval of the breast cancer indication for bevacizumab
based on an assessment of risk-benefit data in women
with metastatic breast cancer (United States Food and
Drug Administration 2011).
Assessing the incidence of grade 3/4 clinical CHF as a
primary end point proved challenging. The present study
did not use the NYHA criteria for CHF, but rather the
NCI CTCAE criteria as used by Miller et al. in ECOG
2100 (Miller et al. 2007). CTCAE contains a variety of
terms that suggest CHF (e.g., dyspnea, shortness of
breath), but CHF can present with a wide range of
signs/symptoms. Many of the symptoms of CHF over-
lap with other disease states such as obesity, chronic
obstructive pulmonary disease, kidney failure, edema,
and liver failure. Using CTCAE, an investigator might
simply identify a symptom as dyspnea, shortness of
breath, or fatigue and not associate the symptom with
left ventricular systolic dysfunction if a recent LVEF
determination was not performed.
There are several important limitations to the study.
While the safety data in this study allow a gauge of the
cardiac safety in the TAC plus bevacizumab and TCH plus
bevacizumab arms of the study, it must be kept in mind
that the quantity of safety data collected in the present
study was less than originally intended, especially for the
TCH plus bevacizumab arm. The sample size of the study
Table 5 Treatment-emergent adverse events (aes) ≥ grade 3, worst grade occurring in at least two subjects overall
Preferred term, n (%) TAC + Bevacizumab (n = 92) TCH + Bevacizumab (n = 34) Total (N = 126)
Subjects with at least one AE≥ grade 3 62 (67.4) 21 (61.8) 83 (65.9)
Neutropenia 37 (40.2) 3 (8.8) 40 (31.7)
Leukopenia 16 (17.4) 2 (5.9) 18 (14.3)
Fatigue 6 (6.5) 5 (14.7) 11 (8.7)
Thrombocytopenia 5 (5.4) 5 (14.7) 10 (7.9)
Hypertension 6 (6.5) 4 (11.8) 10 (7.9)
Abdominal pain 4 (4.3) 0 4 (3.2)
Pain 4 (4.3) 0 4 (3.2)
Nausea 3 (3.3) 1 (2.9) 4 (3.2)
Febrile neutropenia 4 (4.3) 0 4 (3.2)
Headache 1 (1.1) 2 (5.9) 3 (2.4)
Dyspnea 3 (3.3) 0 3 (2.4)
Clinical cardiac failure congestive 3 (3.3) 0 3 (2.4)
Diarrhea 1 (1.1) 1 (2.9) 2 (1.6)
Arthralgia 2 (2.2) 0 2 (1.6)
Vomiting 2 (2.2) 0 2 (1.6)
Decreased appetite 1 (1.1) 1 (2.9) 2 (1.6)
Hot flush 1 (1.1) 1 (2.9) 2 (1.6)
Oropharyngeal pain 2 (2.2) 0 2 (1.6)
Anxiety 2 (2.2) 0 2 (1.6)
Neuropathy peripheral 2 (2.2) 0 2 (1.6)
Back pain 0 2 (5.9) 2 (1.6)
Asthenia 1 (1.1) 1 (2.9) 2 (1.6)
Hyperglycemia 1 (1.1) 1 (2.9) 2 (1.6)
Weight decreased 2 (2.2) 0 2 (1.6)
Proteinuria 1 (1.1) 1 (2.9) 2 (1.6)
Neutrophil count decreased 2 (2.2) 0 2 (1.6)
Postoperative wound infection 2 (2.2) 0 2 (1.6)
Abbreviations: TAC = docetaxel, doxorubicin, cyclophosphamide; TCH = docetaxel, carboplatin, trastuzumab.
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was determined based on the anticipation that the rate of
CHF for bevacizumab would not exceed 2%, while a level
of toxicity above 10% would be of great concern. The
lower than needed number of subjects enrolled in the
TCH arm and decrease in the follow-up period from 10 to
2 years were unanticipated challenges that preclude draw-
ing firm conclusions regarding the relative cardiac safety
of TCH plus bevacizumab.
Conclusion
Cardiac and other toxicities observed in both treatment
strata were consistent with those expected from the
study treatments administered to subjects with node-
positive or high-risk node-negative breast cancer without
bevacizumab. The number of ≥ grade 3 cardiac AEs was
below the prespecified threshold of discontinuation for
these combinations. That said, the overall higher rate of
CHF, particularly LVEF reduction > 10% or LVEF below
the lower limit of normal, observed in the TAC plus bev-
acizumab arm is a concern. The safety data available for
the TCH plus bevacizumab arm indicated that addition
of bevacizumab to a docetaxel regimen with trastuzu-
mab did not increase cardiotoxicity to a threshold sup-
porting cessation of further/future evaluation of this
combination. Originally intended secondary end points
of DFS and OS were not evaluated due to the reduced
follow-up period resulting from a second amendment to
the protocol. Because the number of subjects enrolled
into the TCH with bevacizumab arm was reduced to half
of the originally intended number, all conclusions related
to the safety of TCH with bevacizumab should be inter-
preted with caution.
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